Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer
June 25th 2024Expert breast oncologists examine adjuvant therapy approaches for early-stage hormone receptor-positive breast cancer, emphasizing the distinct treatment strategies and outcomes observed in pre- and post-menopausal patient populations.
Read More
Optimizing Management of HR+/HER2- BC: Future Directions in Care
Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.
Read More
Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition
Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.
Read More
Considerations for Use of ADCs in HER2-Low Breast Cancer
A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.
Read More
ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04
Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.
Read More
Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer
Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.
Read More
Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors
Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.
Read More